Johnson & Johnson reported 15 holdings worth US$799M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 6, 2026
Johnson & Johnson reported 15 holdings worth US$799M as of Jun 30, 2026. Largest: Protagonist Therapeutics, Inc., Nanobiotix Sa and Meiragtx Holdings Plc. Filed Aug 6, 2026 (Form 13F).
- Holdings
- 15
- Value as reported
- US$799M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Protagonist Therapeutics, Inc. | 2.45M | US$300M | 37.6% |
| Nanobiotix Sa | 5.62M | US$212M | 26.5% |
| Meiragtx Holdings Plc | 6.64M | US$89.7M | 11.2% |
| Rapport Therapeutics, Inc. | 1.78M | US$74.4M | 9.3% |
| Contineum Therapeutics, Inc. | 1.98M | US$32.4M | 4.1% |
| Cvrx, Inc. | 4.02M | US$20.7M | 2.6% |
| Xencor, Inc. | 748K | US$12M | 1.5% |
| Cerebras Systems Inc. | 53,586 | US$11.8M | 1.5% |
| Fate Therapeutics, Inc. | 3.38M | US$9.12M | 1.1% |
| Procept Biorobotics Corporation | 358K | US$8.08M | 1.0% |
| Neumora Therapeutics, Inc. | 1.85M | US$3.14M | 0.39% |
| Vor Biopharma Inc. | 53,732 | US$989K | 0.12% |
| Standard Biotools Inc. | 312K | US$257K | 0.03% |
| Adicet Bio, Inc. | 22,779 | US$197K | 0.02% |
| Rallybio Corporation | 0 | US$0 | 0.00% |